2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dominik P. Modest, MD, University of Munich, discusses the German AIO KRK0110 study in metastatic colorectal cancer.
Dominik P. Modest, MD, University of Munich, discusses the German AIO KRK0110 study in metastatic colorectal cancer (CRC).
AIO KRK0110 is a randomized phase III study of fluoropyrimide plus bevacizumab (Avastin) versus fluoropyrimide plus irinotecan and bevacizumab as first-line therapy for metastatic CRC.
This sequence study aims to answer the question of de-escalation in this patient population.
Related Content: